Genelux Corporation announced interim results from ongoing trials evaluating systemic administration of Olvi-Vec in lung cancer patients.
Promising anti-tumor activity and tolerability were observed in patients with relapsed or refractory lung cancers.
Additional lung cancer data is expected throughout 2026 alongside topline data from an ovarian cancer trial.
ORR of 33% in SCLC Trial
Preliminary results show an overall response rate (ORR) of 33% in the SCLC trial, including three partial responses (PRs).
Tumor Shrinkage
Significant tumor shrinkage of approximately 55% and 85% was observed in the highest dose cohort tested in the SCLC trial.
Durability Signals
Exploratory durability signals were observed, with patients showing promising progression-free survival durations.
- The data reinforces the commitment to advancing registration-path trials in lung cancers.
- Genelux aims to establish Olvi-Vec as a differentiated immunotherapeutic agent for multiple types of cancer.
- Topline data from the Phase 3 ovarian cancer trial expected in the second half of 2026 is a pivotal milestone.
The interim data from the lung cancer trials shows promising results for systemic administration of Olvi-Vec, reinforcing the company's focus on addressing unmet medical needs in progressive lung cancers.